Repair of Large Bone Defects with the Use of Autologous Bone Marrow Stromal Cells

Quarto, Rodolfo; Mastrogiacomo, Maddalena; Cancedda, Ranieri; Kutepov, S. M.; Mukhachev, Vladimir; Lavroukov, Alexander; Kon, Elizaveta; Marcacci, Maurilio

doi:10.1056/nejm200102013440516

Cited by 1,223 publications

(819 citation statements)

References 6 publications

Supporting

Mentioning

797

Contrasting

Unclassified

Order By: Relevance

“…However, these attempts have been proven suboptimal because of the slow resorption rate of the hydroxyapatitebased ceramics (Kadiyala et al, 1997;Ohgushi et al, 1989). A few years ago, we first reported a cell-based tissue engineering procedure to treat patients with long bone segmental defects (Quarto et al, 2001). In that study a 100% HA porous ceramic was employed.…”

Section: Discussionmentioning

confidence: 99%

Kinetics of in vivo bone deposition by bone marrow stromal cells within a resorbable porous calcium phosphate scaffold: An X‐ray computed microtomography study

Papadimitropoulos

Mastrogiacomo

Peyrin

et al. 2007

Biotech & Bioengineering

View full text Add to dashboard Cite

Resorbable ceramic scaffolds based on Silicon stabilized tricalcium phosphate (Si-TCP) were seeded with bone marrow stromal cells (BMSC) and ectopically implanted for 2, 4, and 6 months in immunodeficient mice. Qualitative and quantitative evaluation of the scaffold material was performed by X-ray synchrotron radiation computed microtomography (microCT) with a spatial resolution lower than 5 mm. Unique to these experiments was that microCT data were first collected on the scaffolds before implantation and then on the same scaffolds after they were seeded with BMSC, implanted in the mice and rescued after different times. Volume fraction, mean thickness and thickness distribution were evaluated for both new bone and scaffold phases as a function of the implantation time. New bone thickness increased from week 8 to week 16. Data for the implanted scaffolds were compared with those derived from the analysis of the same scaffolds prior to implantation and with data derived from 100% hydroxyapatite (HA) scaffold treated and analyzed in the same way. At variance with findings with the 100% HA scaffolds a significant variation in the density of the different Si-TCP scaffold regions in the pre-and post-implantation samples was observed. In particular a post-implantation decrease in the density of the scaffolds, together with major changes in the scaffold phase composition, was noticeable in areas adjacent to newly formed bone. Histology confirmed a better integration between new bone and scaffold in the Si-TCP composites in comparison to 100% HA composites where new bone and scaffold phases remained well distinct.

show abstract

Section: Discussionmentioning

confidence: 99%

Kinetics of in vivo bone deposition by bone marrow stromal cells within a resorbable porous calcium phosphate scaffold: An X‐ray computed microtomography study

Papadimitropoulos

Mastrogiacomo

Peyrin

et al. 2007

Biotech & Bioengineering

View full text Add to dashboard Cite

show abstract

“…In addition, bone formation was present in only 5% of the coral scaffold. Quarto et al (2001) reported on the use of autologous culture-expanded BMSCs combined with porous hydroxyapatite (HA) in three patients suffering bone segmental defects 4-7 cm long. The results were encouraging, with good graft integration and return to functionality.…”

Section: Treatment Of Bone Lossmentioning

confidence: 99%

Updates on stem cells and their applications in regenerative medicine

Bajada

Mazakova

Richardson

et al. 2008

J Tissue Eng Regen Med

305

188

View full text Add to dashboard Cite

“…Enfin, si les résultats obtenus avec ces nouveaux produits d'IT sont satisfaisants dans des modèles précliniques [30], le nombre d'essais cliniques reste encore trop limité [31]. Ils sont répertoriés pour un nombre faible de patients souffrant principalement de pertes massives de tissu osseux au niveau des os longs (tibia) [32] ou encore pour des applications en chirurgie maxillofaciale [33]. Les difficultés majeures rencontrées pour de tels essais cliniques sont liées aux aspects réglementaires de l'élaboration de ces produits de thérapie innovants (développement des produits d'IT en conditions GMP, good manufacturing practice) pour assurer une parfaite biosécurité pour le patient [52](➜).…”

Section: Différenciation Des Csm Vers Le Lignage Ostéogéniqueunclassified